Open access
Integrated single-cell and bulk transcriptomic analysis reveals an epithelial cell-derived prognostic and immunotherapeutic signature with ADAM12 as a key functional regulator in non-small cell lung cancer
Hai-Lin Liu
Jun-Jie Yu
Yan-Tao Jiang
Xiao-Fei Ma
Wei Luo
Shu-Yue Guo
Lu-Yao Tong
Yi Lu
Zhen-Fa Zhang
Chenguang Li
Jian-Wei Qi
Ting-Ting Qin
Medicine
Abstract
Highlights • Single-cell transcriptomics reveals epithelial heterogeneity shaping NSCLC immunity.• A 101-algorithm ML framework constructs a Prognostic and Immunotherapeutic Signature.• PIS stratifies NSCLC patients by prognosis and immune checkpoint blockade response.• ADAM12 inhibition enhances anti-PD-1 efficacy in preclinical mouse models.